Skip to main content
TipRanks
Go Ultimate75% OFF

Central Asia Lumeichun Biotechnology (ZYLM) Stock Statistics & Valuation Metrics

4 Followers

Total Valuation

Central Asia Lumeichun Biotechnology has a market cap or net worth of $111.59K. The enterprise value is $485.42B.

Market Cap
$111.59K
Enterprise Value
$485.42B

Share Statistics

Central Asia Lumeichun Biotechnology has 637,681 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
637,681
Owned by Insiders
―
Owned by Institutions
―

Financial Efficiency

Central Asia Lumeichun Biotechnology’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.12%.

Return on Equity (ROE)
0.00
Return on Assets (ROA)
0.00
Return on Invested Capital (ROIC)
0.12%
Return on Capital Employed (ROCE)
0.00
Revenue Per Employee
150.75K
Profits Per Employee
549
Employee Count
8
Asset Turnover
0.37
Inventory Turnover
16.14

Valuation Ratios

The current PE Ratio of Central Asia Lumeichun Biotechnology is -21.05. Central Asia Lumeichun Biotechnology’s PEG ratio is -0.30.

PE Ratio
-21.05
PS Ratio
0.87
PB Ratio
1.25
Price to FCF
0.65
Price to Operating Cash Flow
2.06
PEG Ratio
-0.30

Income Statement

In the last 12 months, Central Asia Lumeichun Biotechnology had revenue of 1.21M and earned 4,392 in profits. Earnings per share was 0.00.

Revenue
1.21M
Gross Profit
612.18K
Operating Income
8,005
Pretax Income
9,694
Net Income
4,392
EBITDA
8,005
Earnings Per Share (EPS)
0.00

Cash Flow

In the last 12 months, operating cash flow was 772.10K and capital expenditures -4, giving a free cash flow of 772.10K billion.

Operating Cash Flow
772.10K
Free Cash Flow
772.10K
Free Cash Flow per Share
0.00

Dividends & Yields

Central Asia Lumeichun Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
154.42%
Earnings Yield
-4.75%

Stock Price Statistics

Beta
0.65
52-Week Price Change
-96.52%
50-Day Moving Average
0.17
200-Day Moving Average
0.32
Relative Strength Index (RSI)
38.51
Average Volume (3m)
743

Financial Position

Central Asia Lumeichun Biotechnology as a current ratio of 5.61, with Debt / Equity ratio of 1.71%

Current Ratio
5.61
Quick Ratio
5.47
Debt to Market Cap
0.03
Net Debt to EBITDA
1.88
Interest Coverage Ratio
39.83

Taxes

In the past 12 months, Central Asia Lumeichun Biotechnology has paid 5,302 in taxes.

Income Tax
5,302
Effective Tax Rate
0.55

Enterprise Valuation

Central Asia Lumeichun Biotechnology EV to EBITDA ratio is 39.52, with an EV/FCF ratio of 0.63.

EV to Sales
0.84
EV to EBITDA
39.52
EV to Free Cash Flow
0.63
EV to Operating Cash Flow
0.63

Balance Sheet

Central Asia Lumeichun Biotechnology has $25.13K in cash and marketable securities with $10.55K in debt, giving a net cash position of $14.58K billion.

Cash & Marketable Securities
$25.13K
Total Debt
$10.55K
Net Cash
$14.58K
Net Cash Per Share
$0.02
Tangible Book Value Per Share
$0.00

Margins

Gross margin is 83.73%, with operating margin of 0.57%, and net profit margin of -13.11%.

Gross Margin
83.73%
Operating Margin
0.57%
Pretax Margin
-13.07%
Net Profit Margin
-13.11%
EBITDA Margin
2.13%
EBIT Margin
0.58%

Analyst Forecast

The average price target for Central Asia Lumeichun Biotechnology is ―, which is 11.43% higher than the current price. The consensus rating is ―

Price Target
―
Price Target Upside
―
Analyst Consensus
―
Analyst Count
0
Revenue Growth Forecast
―
EPS Growth Forecast
―